Your browser doesn't support javascript.
loading
Editors' Commentary on the 2023 ESH Management of Arterial Hypertension Guidelines.
Whelton, Paul K; Flack, John M; Jennings, Garry; Schutte, Alta; Wang, Jiguang; Touyz, Rhian M.
Afiliación
  • Whelton PK; Department of Epidemiology, Tulane University School of Public Health and Tropical Medicine, New Orleans, LA (P.K.W.).
  • Flack JM; Hypertension Section, Division of General Medicine, Department of Medicine, Southern Illinois University, Springfield (J.M.F.).
  • Jennings G; Sydney Health Partners, University of Sydney and National Heart Foundation, New South Wales, Australia (G.J.).
  • Schutte A; School of Population Health, University of New South Wales, The George Institute for Global Health, Sydney, Australia (A.S.).
  • Wang J; Shanghai Institute of Hypertension, Shanghai Jiao Tong University School of Medicine, China (J.W.).
  • Touyz RM; Department of Medicine, Faculty of Medicine and Health Sciences, McGill University, Research Institute of the McGill University Health Centre, Montreal, Quebec, Canada (R.M.T.).
Hypertension ; 80(9): 1795-1799, 2023 09.
Article en En | MEDLINE | ID: mdl-37354199
ABSTRACT
Clinical practice guidelines are ideally suited to the provision of advice on the prevention, diagnosis, evaluation, and management of high blood pressure (BP). The recently published European Society of Hypertension (ESH) 2023 ESH Guidelines for the management of arterial hypertension is the latest in a long series of high BP clinical practice guidelines. It closely resembles the 2018 European Society of Cardiology/ESH guidelines, with incremental rather than major changes. Although the ESH guidelines are primarily written for European clinicians and public health workers, there is a high degree of concordance between its recommendations and those in the other major BP guidelines. Despite the large number of national and international BP guidelines around the world, general population surveys demonstrate that BP guidelines are not being well implemented in any part of the world. The level of BP, which is the basis for diagnosis and management, continues to be poorly measured in routine clinical practice and control of hypertension remains suboptimal, even to a conservative BP target such as a systolic/diastolic BP <140/90 mm Hg. BP guidelines need to focus much more on implementation of recommendations for accurate diagnosis and strategies for improved control in those being treated for hypertension. An evolving body of implementation science can assist in meeting this goal. Given the enormous health, social, and financial burden of high BP, better diagnosis and management should be an imperative for clinicians, government, and others responsible for the provision of health care services. Hopefully, the 2023 ESH will help enable this.
Asunto(s)
Palabras clave

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Cardiología / Hipertensión Tipo de estudio: Guideline / Qualitative_research Límite: Humans Idioma: En Revista: Hypertension Año: 2023 Tipo del documento: Article

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Cardiología / Hipertensión Tipo de estudio: Guideline / Qualitative_research Límite: Humans Idioma: En Revista: Hypertension Año: 2023 Tipo del documento: Article